Laboratory Medicine ›› 2017, Vol. 32 ›› Issue (7): 656-662.DOI: 10.3969/j.issn.1673-8640.2017.07.023
• Orginal Article • Previous Articles
GAO Yaoyi, MA Xiaolu, WU Jiong, GUO Wei, PAN Baishen
Received:
2016-06-02
Online:
2017-08-08
Published:
2017-08-09
CLC Number:
GAO Yaoyi, MA Xiaolu, WU Jiong, GUO Wei, PAN Baishen. Role of CD73 in cancer[J]. Laboratory Medicine, 2017, 32(7): 656-662.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2017.07.023
[1] | BURNSTOCK G,VIRGILIO F.Purinergic signaling and cancer[J]. Purinergic Signal,2013,9(4):491-540. |
[2] | HELENIUS M,JALKANEN S,YEGUTKIN G.Enzyme-coupled assays for simultaneous detection of nanomolar ATP,ADP,AMP,adenosine,inosine and pyrophosphate concentrations in extracellular fluids[J]. Biochim Biophys Acta,2012,1823(10):1967-1975. |
[3] | ALLARD B,BEAVIS P A,DARCY P K,et al.Immunosuppressive activities of adenosine in cancer[J]. Curr Opin Pharmacol,2016,29:7-16. |
[4] | YEGUTKIN G G.Nucleotide- and nucleoside-converting ectoenzymes:important modulators of purinergic signaling cascade[J]. Biochim Biophys Acta,2008,1783(5):673-694. |
[5] | STAGG J,SMYTH M J.Extracellular adenosine triphosphate and adenosine in cancer[J]. Oncogene,2010,29(39):5346-5358. |
[6] | GHIRINGHELLI F,BRUCHARD M,CHALMIN F,et al.Production of adenosine by ectonucleotidases:a key factor in tumor immuno-escape[J]. J Biomed Biotechnol,2012,2012:473712. |
[7] | ZHI X,CHEN S,ZHOU P,et al.RNA interference of ecto-5′-nucleotidase(CD73)inhibits human breast cancer cell growth and invasion[J]. Clin Exp Metastasis,2007,24(6):439-448. |
[8] | ZHANG B.CD73 promotes tumor growth and metastasis[J]. Oncoimmunology,2012,1(1):67-70. |
[9] | WANG L,TANG S,WANG Y,et al.Ecto-5'-nucleotidase(CD73)promotes tumor angiogenesis[J]. Clin Exp Metastasis,2013,30(5):671-680. |
[10] | ANTONIOLI L,YEGUTKIN G G,PACHER P,et al.Anti-CD73 in cancer immunotherapy:awakening new opportunities[J]. Trends Cancer,2016,2(2):95-109. |
[11] | ALLARD B,TURCOTTE M,SPRING K,et al.Anti-CD73 therapy impairs tumor angiogenesis[J]. Int J Cancer,2014,134(6):1466-1473. |
[12] | BÖRING Y C,FLÖGEL U,JACOBY C,et al. Lack of ecto-5'-nucleotidase(CD73)promotes arteriogenesis[J]. Cardiovasc Res,2013,97(1):88-96. |
[13] | GIULIANO S,PAGES G.Mechanisms of resistance to anti-angiogenesis therapies[J]. Biochimie,2013,95(6):1110-1119. |
[14] | ZHI X,WANG Y,ZHOU X,et al.RNAi-mediated CD73 suppression induces apoptosis and cell-cycle arrest in human breast cancer cells[J]. Cancer Sci,2010,101(12):2561-2569. |
[15] | ZHOU X,ZHI X,ZHOU P,et al.Effects of ecto-5'-nucleotidase on human breast cancer cell growth in vitro and in vivo[J]. Oncol Rep,2007,17(6):1341-1346. |
[16] | SHIRALI S,AGHAEI M,SHABANI M,et al.Adenosine induces cell cycle arrest and apoptosis via cyclinD1/Cdk4 and Bcl-2/Bax pathways in human ovarian cancer cell line OVCAR-3[J]. Tumour Biol,2013,34(2):1085-1095. |
[17] | ZHI X,WANG Y,YU J,et al.Potential prognostic biomarker CD73 regulates epidermal growth factor receptor expression in human breast cancer[J]. IUBMB Life,2012,64(11):911-920. |
[18] | YEGUTKIN G G,MARTTILA-ICHIHARA F,KARIKOSKI M,et al.Altered purinergic signaling in CD73-deficient mice inhibits tumor progression[J]. Eur J Immunol,2011,41(5):1231-1241. |
[19] | KOSZALKA P,GOLUNSKA M,STANISLA-WOWSKI M,et al.CD73 on B16F10 melanoma cells in CD73-deficient mice promotes tumor growth,angiogenesis,neovascularization,macrophage infiltration and metastasis[J]. Int J Biochem Cell Biol,2015,69:1-10. |
[20] | SADEJ R,SPYCHALA J,SKLADANOWSKI A C.Ecto-5'-nucleotidase(eN,CD73)is coexpressed with metastasis promoting antigens in human melanoma cells[J]. Nucleosides Nucleotides Nucleic Acids,2006,25(9-11):1119-1123. |
[21] | XIONG L,WEN Y,MIAO X,et al.NT5E and FcGBP as key regulators of TGF-1-induced epithelial-mesenchymal transition(EMT)are associated with tumor progression and survival of patients with gallbladder cancer[J]. Cell Tissue Res,2014,355(2):365-374. |
[22] | SADEJ R,SKLADANOWSKI A C.Dual,enzymatic and non-enzymatic,function of ecto-5'-nucleotidase(eN,CD73)in migration and invasion of A375 melanoma cells[J]. Acta Biochim Pol,2012,59(4):647-652. |
[23] | STAGG J,DIVISEKERA U,DURET H,et al.CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis[J]. Cancer Res,2011,71(8):2892-2900. |
[24] | WANG L,ZHOU X,ZHOU T,et al.Ecto-5'-nucleotidase promotes invasion,migration and adhesion of human breast cancer cells[J]. J Cancer Res Clin Oncol,2008,134(3):365-372. |
[25] | LU X X,CHEN Y T,FENG B,et al.Expression and clinical significance of CD73 and hypoxia-inducible factor-1α in gastric carcinoma[J]. World J Gastroenterol,2013,19(12):1912-1918. |
[26] | ANTONIOLI L,PACHER P,VIZI E S,et al.CD39 and CD73 in immunity and inflammation[J]. Trends Mol Med,2013,19(6):355-367. |
[27] | BEAVIS P A,STAGG J,DARCY P K,et al.CD73:a potent suppressor of antitumor immune responses[J]. Trends Immunol,2012,33(5):231-237. |
[28] | KUMAR V.Adenosine as an endogenous immuno-regulator in cancer pathogenesis:where to go?[J]. Purinergic Signal,2012,9(2):145-165. |
[29] | RASKOVALOVA T,HUANG X,SITKOVSKY M,et al.GS protein-coupled adenosine receptor signaling and lytic function of activated NK cells[J]. J Immunol,2005,175(7):4383-4391. |
[30] | NOVITSKIY S V,RYZHOV S,ZAYNAGETDINOV R,et al.Adenosine receptors in regulation of dendritic cell differentiation and function[J]. Blood,2008,112(5):1822-1831. |
[31] | WHITESIDE T L,MANDAPATHIL M,SCHULER P.The role of the adenosinergic pathway in immunosuppression mediated by human regulatory T cells(Treg)[J]. Curr Med Chem,2011,18(34):5217-5223. |
[32] | RYZHOV S,NOVITSKIY S V,GOLDSTEIN A E,et al.Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b+Gr1+cells[J]. J Immunol,2011,187(11):6120-6129. |
[33] | UJHÁZY P,BERLETH E S,PIETKIEWICZ J M,et al. Evidence for the involvement of ecto-5'-nucleotidase(CD73)in drug resistance[J]. Int J Cancer,1996,68(4):493-500. |
[34] | QUEZADA C,GARRIDO W,OYARZÚN C,et al. 5'-ectonucleotidase mediates multiple-drug resistance in glioblastoma multiform cells[J]. J Cell Physiol,2013,228(3):602-608. |
[35] | LOI S,POMMEY S,HAIBE-KAINS B,et al.CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer[J]. Proc Natl Acad Sci U S A,2013,110(27):11091-11096. |
[36] | JIN D,FAN J,WANG L,et al.CD73 on tumor cells impairs antitumor T-cell responses:a novel mechanism of tumor-induced immune suppression[J]. Cancer Res,2010,70(6):2245-2255. |
[37] | SEMENZA G L.Hypoxia-inducible factor 1:Regulator of mitochondrial metabolism and mediator of ischemic preconditioning[J]. Biochim Biophys Acta,2011,1813(7):1263-1268. |
[38] | BRISEVAC D,BJELOBABA I,BAJIC A,et al.Regulation of ecto-5'-nucleotidase(CD73)in cultured cortical astrocytes by different inflammatory factors[J]. Neurochem Int,2012,61(5):681-688. |
[39] | GAUDREAU P O,ALLARD B,TURCOTTE M,et al.CD73-adenosine reduces immune responses and survival in ovarian cancer patients[J]. Oncoimmunology,2016,5(5):e1127496. |
[40] | LO NIGRO C,MONTEVERDE M,LEE S,et al.NT5E CpG island methylation is a favourable breast cancer biomarker[J]. Br J Cancer,2012,107(1):75-83. |
[41] | THOM V T,WENDEL M,DEUSSEN A.Regulation of ecto-5'-nucleotidase by docosahexaenoic acid in human endothelial cells[J]. Cell Physiol Biochem,2013,32(2):355-366. |
[42] | HÄUSLER S F,DEL BARRIO I M,DIESSNER J,et al. Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion[J]. Am J Transl Res,2014,6(2):129-139. |
[43] | STAGG J,DIVISEKERA U,MCLAUGHLIN N,et al.Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis[J]. Proc Natl Acad Sci U S A,2010,107(4):1547-1552. |
[44] | PARDOLL D M.The blockade of immune checkpoints in cancer immunotherapy[J]. Nat Rev Cancer,2012,12(4):252-264. |
[45] | ALLARD B,POMMEY S,SMYTH M J,et al.Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs[J]. Clin Cancer Res,2013,19(20):5626-5635. |
[46] | LANNONE R,MIELE L,MAIOLINO P,et al.Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model[J]. Am J Cancer Res,2014,4(2):172-181. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||